RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (LURBICLIN)

Intergroupe Francophone de Cancerologie Thoracique

Status: Completed

Conditions: Small-cell Lung Cancer

Treatments: Drug: Lurbinectedin

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05285033

IFCT-2105

Details and patient eligibility

About

LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.

Full description

LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received lurbinectedin as part of the French Early Access Program (ATU). Previous and subsequent treatments (treatment delivered immediately after treatment with lurbinectedin) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

Enrollment: 312 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histologically or cytologically confirmed extensive stage Small Cell Lung Cancer
• Patients who were informed about the study and accepted for their data to be collected
• Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
• Selection period spans from June 2020 until March 2021 for initiation of treatment with lurbinectedin.

Exclusion criteria

• Patients enrolled in a clinical trial assessing treatment with lurbinectedin